Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Participants With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Non-Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) and/or Anti-tumor Necrosis Factor (Anti-TNF) Therapy: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Participants With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Non-Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) and/or Anti-tumor Necrosis Factor (Anti-TNF) Therapy (NCT01362062), a registered phase not stated study. The primary outcome is Percentage of Participants With Adverse Events (AEs) or Serious AEs (SAEs).

2. Clinical Question

The central question is descriptive: what safety events were recorded among participants receiving tocilizumab in routine care, and what disease-activity outcomes were intended for observation? Because the study was observational and does not identify a control group, its primary endpoint describes events in the treated cohort rather than estimating a treatment effect relative to another therapy or to no treatment.

The study record describes participants with rheumatoid arthritis who had not responded adequately to current non-biologic DMARD and/or anti-TNF therapy. It does not specify a randomized assignment process. Treatment was given in routine clinical practice, so clinical decisions and participant characteristics may differ from those in a controlled trial. The registry lists the percentage with adverse events or serious adverse events as the primary outcome, with a timeframe of up to 12 months. It also lists measures of change in DAS28, achievement of low disease activity or remission, ACR responses, and ESR change. Numerical efficacy results for those outcomes are not reported in the registry record.

3. Trial Design

This completed study was observational, not a randomized treatment comparison. The registry describes a single RA cohort receiving tocilizumab in routine clinical practice. The record does not identify a concurrent control group, and allocation is not stated. Consequently, the study can describe events and outcomes observed in the cohort, but the record does not support a direct comparison of tocilizumab with another treatment group.

The study enrolled 110 participants. Its brief description says information was collected during tocilizumab therapy and follow-up for a total of 12 months. The primary endpoint timeframe is stated as up to 12 months. The record describes participants with moderate to severe active rheumatoid arthritis who had an inadequate response to current non-biologic DMARD and/or anti-TNF therapy. It says treatment was used according to routine clinical practice and in line with prescribing information.

The primary outcome concerns the percentage of participants with adverse events or serious adverse events. A serious adverse event is defined by criteria including death or a life-threatening event, inpatient hospitalization or prolongation of hospitalization, persistent or significant disability, a congenital abnormality or birth defect, or medical significance. Adverse events include serious and non-serious events. The safety analysis population is described as participants who received at least 1 dose of study drug.

The registry lists 14 outcome measures and 66 analyses, but does not report the full statistical plan, details of how the prospective and retrospective portions were handled, or the approach used to select analyses for reporting. The record does not report a sample-size justification. The study dates are listed as 2010-10-26 for the start and 2015-01-01 for primary completion; these dates describe the registry record and should not be confused with each participant’s follow-up period.

Because treatment was observed in usual practice, exposure and follow-up may reflect clinical decisions rather than a fixed trial schedule. The record does not report how deviations from intended treatment, changes in therapy, or incomplete follow-up were handled. These design features matter when interpreting both safety counts and any disease-activity outcomes.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Safety analysis population: Included all participants who received at least 1 dose of study drug.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: All enrolled participants who were considered evaluable for analysis.

6. Primary Endpoint

The registry lists the primary outcome as Percentage of Participants With Adverse Events (AEs) or Serious AEs (SAEs), measured over Up to 12 months.

The primary endpoint measures the percentage of participants who experienced adverse events or serious adverse events during follow-up of up to 12 months. An adverse event is defined broadly as an unfavorable and unintended sign, symptom, or disease, including an abnormal laboratory finding, that occurs in temporal association with use of a medicinal product, whether or not it is considered related to that product. The registry definition includes both serious and non-serious events.

Seriousness is based on specified consequences or clinical importance, not simply on how intense a symptom feels. The registry’s criteria include a fatal or life-threatening event, inpatient hospitalization or prolongation of hospitalization, persistent or significant disability, a congenital abnormality or birth defect, or an event considered medically significant. This distinction is useful because a safety summary can separate events meeting seriousness criteria from other adverse events.

A percentage endpoint expresses how common a recorded event was within the defined safety population over the stated observation period. It does not, by itself, establish that the treatment caused the event. In an observational cohort, events can arise from the underlying illness, other treatments, participant characteristics, or factors not measured in the record. The registry’s endpoint is therefore primarily descriptive: it summarizes events recorded among participants who received at least 1 dose of study drug.

The posted results list 8 participants with serious adverse events and 35 with other adverse events in the RA cohort, with 110 at risk in each category. These are separate entries in the safety summary; the record does not explain whether participants represented in one category also appear in the other. The registry does not report a causal comparison or a complete event-level account in the registry record for this analysis.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

What does a percentage of participants mean?

For a binary outcome, each participant is classified according to whether the event was recorded during the defined observation period. A percentage then describes the share of the analyzed population with that event. This is a descriptive summary of observed participants. It does not describe how often an event occurred repeatedly within the same participant, and it does not show when the event occurred unless timing is separately reported.

In this registry, the primary outcome is the percentage of participants with adverse events or serious adverse events over up to 12 months. The adverse-event summary lists the participants at risk and those affected for serious and other events. The entries are not a randomized comparison. The record does not state whether the serious and other event categories are mutually exclusive, so the counts should not be combined or treated as separate participant groups.

Why is the study design important?

Randomization, when used, aims to make treatment groups comparable with respect to factors that can affect outcomes. This study is observational, and the record does not identify a randomized comparator. In general, participants receiving treatment in routine care can differ in illness severity, prior treatment, coexisting conditions, and other factors. Those differences can affect the likelihood of both treatment selection and outcomes. This is called confounding. Without a suitable comparison and an adequate adjustment strategy, observed outcomes cannot be attributed to the treatment alone.

The registry says treatment followed routine clinical practice. That can make the observations relevant to the care setting described, but also means treatment and follow-up may vary. The record does not report how changes in therapy, treatment discontinuation, or differences in monitoring were incorporated into the analysis. Those details are important because they can affect the period during which events are observed and which participants contribute data to each endpoint.

What would a confidence interval add?

In general, a confidence interval describes statistical uncertainty around an estimated quantity under a chosen model and sampling framework. A narrower interval indicates greater precision under those assumptions; a wider interval indicates less precision. An interval does not remove bias from confounding, measurement error, or incomplete follow-up. Confidence intervals for the posted primary safety results are not reported in the registry record, so their statistical precision cannot be assessed from the record details available.

For observational safety data, interpretation also depends on how events were collected, checked, and classified. The registry provides definitions for adverse events and serious adverse events, but the registry entries available do not describe adjudication procedures, exposure-adjusted rates, or a causal attribution method. A participant-based percentage and an event rate based on time at risk answer different questions; the latter requires person-time information, which is not reported in the registry record.

How should listed outcome measures be read?

The registry names outcomes related to DAS28, ACR response, and ESR. DAS28 outcomes include clinically meaningful improvement, low disease activity, and remission; ACR outcomes include ACR20, ACR50, ACR70, and ACR90. These labels identify what the study intended to assess, but they are not results. Numerical findings for these outcomes are not reported in the registry record. Their names alone cannot show the magnitude, consistency, or precision of any change.

In general, a change-from-baseline analysis compares a follow-up value with a participant’s starting value. A responder outcome instead classifies participants according to whether they meet a defined criterion. Repeated assessments can describe how outcomes vary over visits, but require a clear approach to missing visits and repeated measurements. The registry record does not report the analysis details needed to determine how these issues were handled for the listed disease-activity measures.

What can planning calculations establish?

In general, a sample-size calculation is a planning exercise based on assumptions about the outcome, effect to detect, significance level, allocation, and analysis. It is not an observed result and is not a substitute for the trial’s actual design or analysis plan. Any planning illustration based on an observed effect is especially limited when the underlying comparison is not randomized and the effect estimate may be confounded. The registry does not report a sample-size justification for this observational study. A calculation under hypothetical two-arm assumptions should therefore not be read as observed power or as evidence that the study was designed to detect a particular effect.

Over-dispersion is a general concern for outcomes whose variability exceeds what a simple statistical model assumes. In general, ignoring it can make uncertainty appear too small. The primary outcome is described as a percentage of participants with an event, and the registry entries do not specify an over-dispersion model or provide the statistical details needed to assess one. No particular model should be inferred from the endpoint label.

Overall, the record gives the study setting, endpoint definitions, and selected safety counts. It does not report a full statistical analysis plan, confidence intervals, model specifications, or details of adjusted analyses. These omissions limit assessment of precision and analytic choices. The most defensible reading is descriptive: the posted safety counts characterize the recorded cohort, while unreported efficacy and analysis details remain unknown.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists 14 outcome measures and 66 analyses. When a study examines many outcomes or performs many analyses, the chance of obtaining a nominally notable result by chance can increase. In general, multiplicity methods can control or describe that risk, but the appropriate approach depends on the prespecified hypotheses and analysis plan. The registry record does not report whether multiplicity was addressed, which outcomes were treated as primary for each analysis, or whether analyses were selected after examining the data. No conclusion about adjustment should be inferred.

The registry identifies the primary safety endpoint and lists secondary disease-activity outcomes, but numerical results for the listed efficacy measures are not reported in the registry record. It also does not report the number of participants contributing data to each outcome at each visit, a missing-data strategy, or sensitivity analyses. In general, missing observations can affect estimates if the probability of missingness is related to participant characteristics or outcomes. The direction and size of that effect cannot be determined without further information.

The safety analysis population includes participants who received at least 1 dose of study drug. The record does not describe whether this population was used consistently for all outcomes or how participants with incomplete follow-up were handled. The registry entries also do not specify how the prospective and retrospective portions of the cohort were combined, whether outcome definitions or data sources differed, or whether any covariate adjustment was performed. Each of these details could affect interpretation, but none should be assumed.

The record does not report a statistical analysis plan, interim analyses, confidence intervals, or a sample-size justification. These omissions make it difficult to distinguish planned analyses from exploratory ones or to assess the precision of results. The reported safety counts remain interpretable as descriptive registry entries, but they do not resolve these broader analytic uncertainties.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: abdominal pain (1.8%), supraventricular tachycardia (0.9%), nausea (0.9%), vomiting (0.9%), diarrhoea (0.9%).

The adverse-event summary lists 8 participants with serious adverse events and 35 with other adverse events in the RA cohort. The number at risk is 110 for each entry. These are registry-reported counts. They are not evidence that the events were caused by tocilizumab, because the endpoint includes events whether or not considered related to the medicinal product. The record does not report a randomized control group against which to compare them.

The serious-event terms listed are abdominal pain at 1.8%, and supraventricular tachycardia, nausea, vomiting, diarrhoea, and acute gastroenteritis at 0.9% each. These percentages should be read as the registry’s entries for the named terms, not as estimates of treatment-attributable risk. The list does not describe event timing, recurrence, resolution, or clinical outcome. It also should not be read as a complete catalogue of every event recorded.

Seriousness follows the registry’s criteria, which include hospitalization, life-threatening or fatal events, significant disability, congenital abnormality or birth defect, and medical significance. Seriousness is distinct from causal relatedness. The summary does not explain whether participants could contribute to both the serious and other event categories, so the counts should not be added together. It is a descriptive safety snapshot from an observational cohort, not a comparative safety estimate.

12. What the Result Does, and Does Not, Mean

The posted results show that adverse events were recorded among participants in this observational rheumatoid arthritis cohort receiving tocilizumab in routine clinical practice. The registry lists serious and other adverse-event counts and gives selected serious-event terms with percentages. These findings describe what the registry reports for the cohort and follow-up period; they do not establish whether tocilizumab caused any individual event or altered event frequency relative to another treatment.

The registry also identifies disease-activity outcomes, including DAS28 improvement, low disease activity, remission, ACR responses, and ESR change. Their numerical results are not reported in the registry record. Listing an outcome does not establish that participants achieved it, nor does it reveal how large or precise any change may have been. No efficacy conclusion can be drawn from the outcome titles alone.

The study’s observational design is central to interpretation. Participants were treated in routine practice, and no randomized comparator is described. In general, differences in participant health, prior treatment, coexisting conditions, and clinical decisions can influence both treatment and outcomes. The record does not report an adjusted comparative analysis that would address such differences. Therefore, these data cannot isolate a treatment effect or show what would have happened to the same participants under a different treatment approach.

The results also do not establish the frequency of events beyond the specified follow-up, the long-term course of the disease, or comparative benefits and harms. The record does not report confidence intervals or key missing-data details, so statistical precision and possible effects of incomplete follow-up cannot be assessed. A count in an observational safety summary is informative as a description of recorded events, but it is not a causal risk estimate.

In short, the registry supports a limited descriptive reading of safety reporting in the cohort. It does not support a randomized comparison, a causal safety claim, or an efficacy claim in the registry record. Unreported analyses and outcomes should remain unknown rather than being inferred from the study’s stated aims.

13. Why This Trial Matters Statistically

This study is statistically informative because it illustrates the difference between describing outcomes and estimating a comparative treatment effect. An observational cohort can document adverse events and clinical outcomes during routine care. But without a randomized comparator, differences in participant characteristics and treatment decisions can complicate any attempt to attribute outcomes to the treatment. That distinction applies even when an endpoint is clearly defined and event counts are reported.

The registry gives a defined safety population, a follow-up timeframe, and criteria separating serious adverse events from other adverse events. Those details help readers understand what the safety summary is intended to count. It also lists disease-activity measures, including DAS28, ACR responses, and ESR. However, the numerical efficacy results and several important analysis details are not reported in the registry record. This shows why outcome definitions and outcome findings are different kinds of information.

The record also lists many outcome measures and analyses. In general, multiple analyses make prespecification and transparent reporting important: readers need to know which questions were primary, how uncertainty was quantified, and whether any multiplicity approach was used. Those details are not reported in the registry record. This limits the ability to evaluate how the posted analyses were selected and how precisely they answer the stated questions.

Finally, registry safety counts should be interpreted in context. Events recorded during treatment are not automatically caused by treatment, and a descriptive cohort cannot supply the counterfactual comparison needed to estimate what would have occurred under another strategy. Recognizing those boundaries makes the reported information useful without assigning it a stronger meaning than the design supports.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The most important limitation is the observational design. The record describes routine clinical use of tocilizumab and does not identify a randomized comparator. Allocation is not stated, and the registry explicitly indicates that the cohort is not a like-for-like control comparison. As a result, the reported safety figures cannot establish comparative risk or isolate a treatment effect from other influences.

The record does not report numerical findings for the listed disease-activity outcomes. Although DAS28, ACR, and ESR measures are named, their observed results and precision are not available in the registry record. The primary safety endpoint is described, but confidence intervals and a full statistical analysis plan are not reported. This limits assessment of uncertainty and analytic choices.

The registry identifies a safety analysis population consisting of participants who received at least 1 dose of study drug. It does not describe the analysis population used for every other outcome, how incomplete follow-up was handled, or how missing observations were addressed. It also does not explain how prospective and retrospective data were combined or whether event collection and assessment differed between those sources.

The adverse-event summary includes counts and selected serious-event terms, but the record does not provide a complete event-level account in the registry record. It does not report event timing, duration, recurrence, outcome, exposure-adjusted rates, or the method used to assess causal relatedness. The categories of serious and other adverse events should not be assumed to be mutually exclusive.

Finally, the registry does not report a sample-size justification, interim analyses, or whether multiplicity was addressed despite listing many outcomes and analyses. These missing details do not invalidate the descriptive counts, but they restrict the conclusions that can be drawn about precision, completeness, and the strength of any broader interpretation.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Participants With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Non-Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) and/or Anti-tumor Necrosis Factor (Anti-TNF) Therapy — NCT01362062.
• Registry record last updated 2017-08-02; status last verified 2017-06.
• Results first posted 2016-04-04.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry record describes a completed observational study of tocilizumab in participants with moderate to severe active rheumatoid arthritis and an inadequate response to current non-biologic DMARD and/or anti-TNF therapy. It lists an enrollment of 110 and follow-up during therapy for a total of 12 months. Treatment was given according to routine clinical practice.

The primary endpoint was the percentage of participants with adverse events or serious adverse events up to 12 months. The safety summary lists 8 participants with serious adverse events and 35 with other adverse events, with 110 at risk in each category. Selected serious-event terms and their registry percentages are also reported.

The registry lists disease-activity outcomes, including DAS28, ACR responses, and ESR change, but numerical efficacy findings are not reported in the registry record. A randomized comparator, a full statistical plan, confidence intervals, multiplicity methods, and missing-data procedures are also not reported in the registry record. The results therefore support a descriptive account of the posted safety data, not a causal or comparative treatment-effect conclusion.